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There has been a dramatic increase in pathogen resistance to both pharmaceutical and agrochemical antimicrobial agents. New 
prototypes (lead compounds) are needed to address this situation. In this connection, oxazoline analogues 3a-were evaluated in 
vitro for their efficacy as antimicrobial agents against representative strains of Gram-positive (S. aureus, S. aureus (MRSA), E. 
aerogens, M. luteus.) and Gram-negative bacteria (K. pneumonia, S. typhimurium, S. paratyphi- B, P. vulgaris) and, fungi (C. 
albicans, B,. cinerea, M. Pachydermatis, C krusei) by disc diffusion and minimum inhibitory concentration studies. Among the series 
3a-n, compounds 3b, 3c, 3e, 3h, 3i and 3mshowed potent antimicrobial activities,when compared to the standard drug. 
 










Antibiotics are one of our most important weapons in fighting bacterial infections and have greatly benefited the 
health-related quality of human life since their introduction (Appelbaum & Hunter,2000; Ball, 2000). Howeverin the 
current scenario, there is an alarming increase in life threatening microbial infections especially in immune 
compromised individuals suffering from cancer, AIDS, etc (Vanden et al. 1998; Andriole, 1998; Boruah & Skibo, 1994; 
Ghannooun & Rice, 1999). There has been a constant effort by the scientists to develop more effective and safe 
antimicrobial drugs to battle with microbial infections (Graybill, 1992; Rinaldi, 1992; Walsh, 1993; Warnock, 1995;  
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Georgopapadakou & Walsh, 1996). In spite of the development of several new antimicrobial agents, their clinical 
value is limited to treat an increasing array of life threatening systemic infections because of their relatively high risk 
of toxicity, emergence of drug resistant strains, pharmacokinetic differences, and/or inadequacies in their 
antimicrobial activity (Emami et al. 2004). Therefore, a great need for a more potent and broad spectrum 
antimicrobial agents with reduced side effects (Graybill, 1996). Also, it is essential to investigate newer drugs with 
lesser resistance. Systematic studies among various pharmacological compounds have revealed that any drug may 
have the possibility of possessing diverse functions and thus may have useful activity in completely different spheres 
of medicine.For instance, nitrogen heterocycles in general oxazoline and its analogues in particular are the most 
exploring fields in heterocyclic chemistry due to their diverse biological activities such as anti-inflammatory (Khanum 
et al. 2008), anti-fungal (Lei et al. 2008), anti-cancer  (Yadav et al. 2011) and anti-bacterial (Correia et al. 2011) 
activity. In continuation of 
our(Khanum et al. 2005)ongoing 
program to develop antimicrobial 
agents has inspired us to evaluate in 
vitro antimicrobial study of 2-aryloxy 
methyl oxazoline analogues. 
 
2. EXPERIMENTAL  
The synthetic sequence is outlined in 
Scheme 1. A mixture of 1a-n, chloro 
acetic acid in acetone and anhydrous 
potassium carbonate was refluxed 
for 8 h, cooled and the solvent 
removed under reduced pressure. 
The residual mass was triturated with 
ice water to remove potassium 
carbonate, extracted with ether and 
the ether layer was washed with 10% 
sodium hydroxide solution followed 
by distilled water. The ether layer 
was dried over anhydrous sodium 
sulphate and evaporated to dryness 
to get crude solid, which on 
recrystallization with ethanol gave 
pure substituted aryloxy ethanoic acids (2a-n). A mixture of 2a-n and ethanolamine was subjected to microwave 
irradiation operating at its 20% power for 5-10 min. The reaction mixture was extracted into ether, washed with 
distilled water and dried over anhydrous sodium sulphate. After evaporation of ether layer the crude solid was 
recrystallized with ethanol to afford 2-aryloxy methyl oxazolines (3a-n). The compounds 2a-nand 3a-nwere 
characterized by IR, 1H NMR and mass spectrophotometer (Khanum et al. 2008). 
 
3. PHARMACOLOGY  
3.1. Materials and methods for the antimicrobial activity 
Streptomycin and ciprofloxacin (Sigma) were used as positive controls against bacteria. Fluconazole and ketoconazole 
(Himedia, Mumbai) were used as positive controls against fungi.  
 
3.2. Tested microbes 
The following gram positive bacteria were used for the experiments; S. aureus, S. aureus (MRSA), E. aerogens, M. 
luteus. The gram negative bacteria included, K. pneumonia, S. typhimurium, S. paratyphi- B, P. vulgaris. In addition, 
fungi C. albicans, B,. cinerea, M. pachydermatis, C krusei were also used for the experiments. All cultures were 
obtained from the Department of Microbiology, Manasagangotri, Mysore. 
 
3.3. Preparation of inoculums 
 Bacterial inoculums were prepared by growing cells in Mueller Hinton Broth (MHA) (Himedia) for 24 h at 37 oC. These 
cell suspensions were diluted with sterile MHB to provide initial cell counts of about 104 CFU/ml. The filamentous 
fungi were grown on sabouraud dextrose agar (SDA) slants at 28 oC for 10 days and the spores were collected using  
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sterile doubled distilled water and homogenized. Yeast was grown on sabouraud dextrose broth (SDB) at 28 oC for 48 
h. 
 
3.4. Disc diffusion assay 
Antibacterial activity was carried out using a disc diffusion method (Murray et al. 1995). Petri plates were prepared 
with 20 ml of sterile Mueller Hinton Agar (MHA) (Himedia, Mumbai). The test cultures were swabbed on the top of 
the solidified media and allowed to dry for 10 mins. The tests were conducted at 1000 mg/disc. The loaded discs were 
placed on the surface of the medium and left for 30 min at room temperature for compound diffusion. Negative 
control was prepared using respective solvent. Streptomycin (10 mg/disc) was used as positive control. The plates 
were incubated for 24 h at 37 oC for bacteria and 48 h at 27 oC for fungi. Zone of inhibition was recorded in 
millimeters and the experiment was repeated twice. 
 
3.5. Minimum inhibitory concentration (MIC) 
Minimum inhibitory concentration studies of compounds were performed according to the standard reference 
method for bacteria (Duraipandiyan & Ignacimuthu, 2009) and filamentous fungi (Rex et al. 2008).Required 
concentrations (1000 mg/ml, 500 mg/ml, 250 mg/ml, 125 mg/ml, 62.5 mg/ml, 31.25 mg/ml and 15.62 mg/ml) of the 
compound was dissolved in DMSO (2%), and diluted to give serial two-fold dilutions that were added to each medium 
in 96 well plates. An inoculum of 100 ml from each well was inoculated. The anti-fungal agents ketoconazole, 
fluconazole for fungi and streptomycin, ciprofloxacin for bacteria were included in the assays as positive controls. For 
fungi, the plates were incubated for 48-72 h at 28oC and for bacteria the plates were incubated for 24 h at 37 oC. The 
MIC for fungi was defined as the lowest extract concentration, showing no visible fungal growth after incubation time. 
5 ml of tested broth was placed on the sterile MHA plates for bacteria and incubated at respective temperatures. The 
MIC for bacteria was determined as the lowest concentration of the compound inhibiting the visual growth of the test 
cultures on the agar plate. 
 
4. RESULTS AND DISCUSSION 
Compounds 3a-nhas been prepared as previously reported by our group (Khanum et al. 2008). The antimicrobial 
activities of compounds 3a-nwere screened against eight bacteria and four fungi using in-vitro disc diffusion method. 
The results revealed that most of the compounds exhibited antimicrobial activities against Staphylococcus aureus, 
Staphylococcus aureus (MRSA), Enterobacter aerogens, Micrococcus luteus, Klebsiella pneumonia, Salmonella 
typhimurium, Salmonella paratyphi-B, Proteus vulgaris, Candida albicans, Botyritis cinerea, Malassesia pachydermatis, 
and Candida kruseiorganisms. The results are summarized in Table 1 and 2. Compounds 3b, 3c, 3e, 3h, 3iand 3m  
Table 1 
In-vitro antibacterial activity of compounds 3a-n 
 
Compounds 
Zone of inhibition in mm 











3a 10 9 9 11 9 11 8 12 
3b 25 17 18 21 16 23 16 19 
3c 24 14 19 17 15 24 9 18 
3d 12 10 13 11 9 15 9 11 
3e 23 20 25 27 27 29 30 29 
3f 10 11 12 11 12 9 8 9 
3g 11 11 10 11 9 10 8 9 
3h 21 15 20 21 15 24 13 17 
3i 20 12 14 16 17 19 12 13 
3j 11 8 9 12 11 10 8 9 
3k 16 12 15 13 14 16 9 10 
3l 10 9 9 10 9 11 8 10 
3m 19 12 14 15 16 18 11 18 
3n 17 13 16 14 15 17 10 11 
Streptomycin 18 21 23 26 23 25 19 25 
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showed good activity more than standard drug against S. aureus. Compound 3e with a chloro group at another 
position in the phenyl ring showed good activity against both Gram-positive and Gram-negative bacteria among 
theseries of compounds3a-n compared with the standard drug streptomycin. On the other hand, compounds 3d, 3f, 
3g and 3lwithmethyl groupand 3j, 3k and 3n with nitro group showed less activity. Interestingly compounds 3c and 3h 
with bromo group at ortho and para position respectively, and compound 3i with the Fluoro group at the para 
position in the phenyl ring shown good activity against S. aureus. Compound 3e showed significant antifungal activity 
against B. cinerea and C. krusei. Compounds3h with bromo group at para position and 3i with the fluoro group at the 
para position showed more activity against the compared to standard drug. Further, compound 3m with the fluoro 
group at ortho position showed more activity against  C. albican and compounds3band 3c with chloro and bromo 
groups at para and ortho position respectively, showed more activity against M. pachydermatis strain. In contrast, 
compounds 3a,3d, 3f, 3g, 3j-l and 3nexhibited less activity. The MIC values of active compounds 3b, 3c, 3e, 3h, 3i and 
3magainst bacteria and fungi are given in Table 3 and 4. Significant MIC values were observed against Gram positive 
and Gram negative bacteria. Compounds 3b, 3c and 3h showed good activity against S. aureus. In comparison to  
Table 2 
In-vitro antifungal activity of compounds 3a-n 
 Zone of inhibition in mm 
Compounds 
C. albicans B. cinerea M. pachydermatis 
C. 
krusei 
3a 9 8 10 11 
3b 14 10 26 16 
3c 14 10 25 13 
3d 10 9 15 14 
3e 18 16 21 23 
3f 9 8 10 7 
3g 10 9 9 11 
3h 13 14 11 19 
3i 12 10 13 20 
3j 9 13 8 8 
3k 9 12 13 15 
3l 11 13 15 14 
3m 23 9 12 15 
3n 11 9 13 10 
Ketoconazole 22 14 24 18 
Table 3 
MIC (mg/ml) of compounds tested against bacteria 
 
Compounds 
Minimum inhibitory concentration ( g/ ml) 










3b 15.62 250 250 32.5 250 31.25 500 62.5 
3c 15.62 125 62.5 125 250 15.62 500 125 
3e 31.25 62.5 15.62 15.62 15.62 15.62 125 <15.62 
3h 15.62 250 62.5 62.5 550 31.25 500 125 
3i 31.25 125 125 63.5 63.5 250 125 250 
3m 62.5 500 500 250 250 125 500 500 
Streptomycin 6.25 >100 25 6.25 6.25 30 ni 6.25 
Ciprofloxacin <0.78 >100 <0.78 >100 <0.78 >100 6.25 <0.78 
ni =  no inhibition 
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compounds 3e and 3i, in compounds 3b, 3c and 3hthe potency against S. aureushave been increased by one fold. 
Interestingly the presence of chloro group in 3b and bromogroup in 3c and 3hat the phenyl ring increased the 
potency against S. aureus by two fold compared to fluoro group in 3m. In comparison to compound 3m in compound 
3e the potency is increased by two fold against bacteria S. paratyphi-B, three fold by S. aureus (MRSA) and S. 
typhimurium, four fold by M. luteus, K. and pneumonia and fivefold by E. aerogens. Besides, the potency of 
compound 3e is increased by two fold against fungi B. cinerea, three fold by C. kruseiand four fold by C. albicans 
compared to compound 3m. In general, compound 3eshowed better activity than standard drugs for most of the 
tested bacteria and fungi. 
 
5. CONCLUSION 
Investigation of antibacterial and antifungal screening data revealed that title compounds 3a-nare new promising 
antimicrobials. These novel compounds were evaluated for their activities against eight bacteria and four fungi. 
Compound 3e with a chloro group at ortho position in phenyl ring was found to be more than 1.6 times active against 
S. aureus (MRSA) bacteria than streptomycin and ciprofloxacin. Moreover more than 6.4 times active against M. 
luteus and S. typhimurium bacteria than ciprofloxacin. Compound 3ewas also found to be more than 3.2 times active 
against C. albicans fungi than fluconazole. In contrast, compounds 3a, 3d, 3f, 3g, 3j-l and 3n exhibited lowest 
activity.These results showed that synthesized compound 3emight be a potential antibacterial and anti-fungal agent. 
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